Kathryn Romano, Chief Accounting Officer at Krystal Biotech, Inc. (KRYS), sold 11,023 shares at $164.60 ($1.8M) on 2024-02-28, disclosed to the SEC on 2024-03-01.
Scheduled sale ($1.8M) by Chief Accounting Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $162.73 | 637 | $104K | 5.7% |
| 2 | $162.73 | 637 | $104K | 5.7% |
| 3 | $163.13 | 523 | $85K | 4.7% |
| 4 | $163.13 | 523 | $85K | 4.7% |
| 5 | $163.49 | 786 | $129K | 7.0% |
| 6 | $163.49 | 786 |
| $129K |
| 7.0% |
| 7 | $164.60 | 744 | $122K | 6.7% |
| 8 | $164.60 | 744 | $122K | 6.7% |
| 9 | $164.84 | 1,600 | $264K | 14.4% |
| 10 | $165.22 | 130 | $21K | 1.2% |
| 11 | $166.04 | 200 | $33K | 1.8% |
| 12 | $166.22 | 100 | $17K | 0.9% |
| 13 | $168.91 | 700 | $118K | 6.5% |
| 14 | $169.10 | 1,133 | $192K | 10.5% |
| 15 | $169.10 | 1,133 | $192K | 10.5% |
| 16 | $169.47 | 203 | $34K | 1.9% |
| 17 | $169.75 | 210 | $36K | 2.0% |
| 18 | $171.45 | 100 | $17K | 0.9% |
| 19 | $171.66 | 134 | $23K | 1.3% |
| Total | $165.70 avg | 11,023 | $1.8M | 100% |
| Filing → |
| KRYS | SELL | 2025-02-28 | $131K | — | Filing → |
| KRYS | SELL | 2024-03-01 | $1.4M | — | Filing → |
| KRYS | SELL | 2024-02-28 | $1.1M | — | Filing → |